TrialAllergy2025

CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.

Sarbjit S Saini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.